home
portfolio
team
careers
contact
investor portal
home
portfolio
team
careers
contact
investor portal
Nextech Invest
Blueprint Medicines Debuts Preclinical Data for First-in-Class RET Drug Candidate
Blueprint Medicines Debuts Preclinical Data for First-in-Class RET Drug Candidate
Post navigation
Previous Post
Previous
Blueprint Medicines Receives FDA Authorization to Proceed with Clinical Trials for Two Drug Candidates
Next Post
Next
MacroGenics Presents Updated Data from Phase 1 Study of Margetuximab at ASCO Annual Meeting 2015